Search

Your search keyword '"Freeman, Samuel S."' showing total 115 results

Search Constraints

Start Over You searched for: Author "Freeman, Samuel S." Remove constraint Author: "Freeman, Samuel S." Database Unpaywall Remove constraint Database: Unpaywall
115 results on '"Freeman, Samuel S."'

Search Results

1. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy

2. Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector

3. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

4. Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

5. Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

6. Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

7. Supplementary Figures and Tables from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

8. Supplementary Figures and Tables from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

9. Table S2 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

10. Table S3 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

11. Supplementary Methods from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

12. Supplementary Figure Legends from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

13. Data from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

14. Table S4 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

15. Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

16. Supplementary Figures 1-4 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

17. Supplementary Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

18. Table S3 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

19. Data from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

20. Table S1 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

21. Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

22. Table S1 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

23. Supplementary Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

24. Table S8 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

25. Table S5 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

26. Table S7 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

27. Supplementary Figure Legends from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

28. Table S7 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

29. Supplementary Figures 1-4 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

30. Table S5 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

31. Supplementary Tables 1-8 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

32. Supplementary Methods from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

33. Table S4 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

34. Supplementary Tables 1-8 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

35. Table S6 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

36. Table S2 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

37. Table S6 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

38. Table S8 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

39. Supplementary Figure 4 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

40. Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

41. Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

42. Supplementary Figure 5 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

43. Supplementary Figure 16 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

44. Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

45. Supplementary Figure 8 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

46. Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

47. Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

48. Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

49. Supplementary Figure 10 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

50. Supplementary Figure 7 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

Catalog

Books, media, physical & digital resources